BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) has earned an average rating of “Hold” from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $31.3750.
A number of equities research analysts recently commented on the stock. Jefferies Financial Group lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and upped their price target for the company from $30.00 to $31.00 in a report on Thursday, July 23rd. Benchmark lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Monday, August 10th. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, Craig Hallum lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a report on Wednesday, July 22nd.
Get Our Latest Stock Analysis on BioLife Solutions
Institutional Investors Weigh In On BioLife Solutions
BioLife Solutions Price Performance
Shares of BioLife Solutions stock opened at $36.97 on Friday. BioLife Solutions has a one year low of $17.86 and a one year high of $38.10. The business’s 50 day simple moving average is $30.12 and its two-hundred day simple moving average is $24.77. The stock has a market capitalization of $1.81 billion, a P/E ratio of 31.87 and a beta of 1.93.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%.The firm had revenue of $28.47 million during the quarter, compared to analyst estimates of $27.80 million. Sell-side analysts expect that BioLife Solutions will post 0.03 earnings per share for the current fiscal year.
BioLife Solutions Company Profile
BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.
The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.
Featured Articles
- Five stocks we like better than BioLife Solutions
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
